Growth Metrics

Palvella Therapeutics (PVLA) EBT (2016 - 2024)

Historic EBT for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$4.0 million.

  • Palvella Therapeutics' EBT fell 12854.56% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 7402.68%. This contributed to the annual value of -$17.4 million for FY2024, which is 19327.48% down from last year.
  • Per Palvella Therapeutics' latest filing, its EBT stood at -$4.0 million for Q4 2024, which was down 12854.56% from -$6.8 million recorded in Q3 2024.
  • Over the past 5 years, Palvella Therapeutics' EBT peaked at $13.8 million during Q4 2023, and registered a low of -$19.0 million during Q3 2021.
  • Its 5-year average for EBT is -$7.8 million, with a median of -$9.2 million in 2021.
  • Its EBT has fluctuated over the past 5 years, first crashed by 150869.0% in 2020, then soared by 22393.45% in 2023.
  • Over the past 5 years, Palvella Therapeutics' EBT (Quarter) stood at -$12.4 million in 2020, then increased by 11.27% to -$11.0 million in 2021, then dropped by 1.48% to -$11.2 million in 2022, then skyrocketed by 223.93% to $13.8 million in 2023, then tumbled by 128.55% to -$4.0 million in 2024.
  • Its EBT stands at -$4.0 million for Q4 2024, versus -$6.8 million for Q3 2024 and -$4.2 million for Q2 2024.